<code id='05FC4F0A37'></code><style id='05FC4F0A37'></style>
    • <acronym id='05FC4F0A37'></acronym>
      <center id='05FC4F0A37'><center id='05FC4F0A37'><tfoot id='05FC4F0A37'></tfoot></center><abbr id='05FC4F0A37'><dir id='05FC4F0A37'><tfoot id='05FC4F0A37'></tfoot><noframes id='05FC4F0A37'>

    • <optgroup id='05FC4F0A37'><strike id='05FC4F0A37'><sup id='05FC4F0A37'></sup></strike><code id='05FC4F0A37'></code></optgroup>
        1. <b id='05FC4F0A37'><label id='05FC4F0A37'><select id='05FC4F0A37'><dt id='05FC4F0A37'><span id='05FC4F0A37'></span></dt></select></label></b><u id='05FC4F0A37'></u>
          <i id='05FC4F0A37'><strike id='05FC4F0A37'><tt id='05FC4F0A37'><pre id='05FC4F0A37'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:5
          Scanned cerebellum of a mouse brain, affected by Niemann-Pick Type C, shown in pink and teal — biotech coverage from STAT
          The cerebellum of a mouse brain affected by Niemann-Pick Type C. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

          About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients. 

          A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons. 

          advertisement

          NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests  later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Listen: BridgeBio's big week & Lilly's Alzheimer's data
          Listen: BridgeBio's big week & Lilly's Alzheimer's data

          SammyKimballforSTATWhatcanHomerteachusaboutbiotech?HasBigSciencegottentoobig?Andwhat’sthefutureoftre

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Eyeing GLP

          AdobeDigitaltherapeuticscompanyClickTherapeuticsannouncedWednesdayitwillacquiretheassetsofBetterTher